Trinity Nuclein Series C QP Investors
Trinity Nuclein Series C QP Investors LLC
Trinity Nuclein Series C QP Investors LLC is an investment entity associated with Trinity Investors, a distinguished private equity firm. This vehicle is primarily aimed at funding Nuclein, a biotechnology innovator dedicated to creating advanced rapid diagnostic testing solutions for infectious diseases.
Products & Team
DASH® Rapid PCR System
The DASH® Rapid PCR System is a cutting-edge diagnostic tool that delivers highly accurate PCR test results within a mere 15 minutes, suitable for use at the point of care. It addresses the complexities and delays of conventional diagnostic testing by offering rapid and highly reliable results in a variety of healthcare settings.
The DASH® system solves the critical issue of slow and complicated diagnostic testing, ensuring that healthcare providers can swiftly identify infections such as SARS-CoV-2 and Flu A/B, thereby improving patient outcomes and operational efficiencies.
Nuclein's technology addresses the need for swift and reliable testing solutions to combat the lengthy turnaround times and potential inaccuracies associated with traditional diagnostic testing methods during critical public health scenarios.